Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln — Flagstaff, Arizona

Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln is a clinical research site located in Flagstaff, Arizona, United States 86001-6299.

Crixeo Health Trust Score: 59/100 (POOR). This profile has not yet been claimed by the site owner.

Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln has participated in 3 clinical trials with 3 currently active.

Therapeutic areas: Sjögren's Syndrome (SS), Sjögren's Syndrome, Sjogren's Syndrome.

Sponsors: Amgen.

Sponsor Feasibility Report

Trust Score: 59/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln?

Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln has a Crixeo Trust Score of 59/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln conducted?

Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln has 3 clinical trials on record, with 3 currently active. Their work covers Sjögren's Syndrome (SS), Sjögren's Syndrome, Sjogren's Syndrome.

Is Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln accredited by Crixeo Health?

Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.